Literature DB >> 9780111

Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome.

C B Yang1, S F Freedman, J S Myers, E G Buckley, L W Herndon, R R Allingham.   

Abstract

PURPOSE: To determine if latanoprost reduces intraocular pressure in eyes with glaucoma associated with Sturge-Weber syndrome.
METHODS: We conducted a prospective study in which eyes with uncontrolled intraocular pressure associated with Sturge-Weber syndrome were treated with latanoprost 0.005% once daily. All eyes were already receiving at least two other antiglaucoma medications. Intraocular pressure was measured at baseline and after treatment for at least 1 month. All intraocular pressure measurements were taken within 24 hours of drug instillation.
RESULTS: Six eyes of six patients received latanoprost. Two (28%) of the six eyes demonstrated an intraocular pressure decrease that averaged 8.8 mm Hg. These two responders had juvenile onset glaucoma, whereas the four nonresponders had congenital onset glaucoma.
CONCLUSIONS: Latanoprost may significantly reduce intraocular pressure in selected patients with glaucoma associated with Sturge-Weber syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780111     DOI: 10.1016/s0002-9394(98)00129-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Results of external beam radiotherapy for diffuse choroidal hemangiomas in Sturge-Weber syndrome.

Authors:  Matthieu Randon; Christine Lévy-Gabriel; Rachid Abbas; Rémi Dendale; Livia Lumbroso; Laurence Desjardins; Nathalie Cassoux
Journal:  Eye (Lond)       Date:  2018-02-06       Impact factor: 3.775

2.  Focal venous hypertension as a pathophysiologic mechanism for tissue hypertrophy, port-wine stains, the Sturge-Weber syndrome, and related disorders: proof of concept with novel hypothesis for underlying etiological cause (an American Ophthalmological Society thesis).

Authors:  Cameron F Parsa
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

3.  Sturge-weber syndrome.

Authors:  Catherine D Bachur; Anne M Comi
Journal:  Curr Treat Options Neurol       Date:  2013-10       Impact factor: 3.598

4.  Long-term efficacy of latanoprost in primary congenital glaucoma.

Authors:  M G Uva; T Avitabile; M Reibaldi; C Bucolo; F Drago; L Quaranta; E Lionetti; A Longo
Journal:  Eye (Lond)       Date:  2013-10-25       Impact factor: 3.775

Review 5.  Ocular Manifestations of the Sturge-Weber Syndrome.

Authors:  Kiana Hassanpour; Ramin Nourinia; Ebrahim Gerami; Ghavam Mahmoudi; Hamed Esfandiari
Journal:  J Ophthalmic Vis Res       Date:  2021-07-29

6.  Latanoprost in port wine stain related paediatric glaucoma.

Authors:  T Ong; A Chia; K K Nischal
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

Review 7.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  The management of complicated glaucoma.

Authors:  C I Clement; Ivan Goldberg
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

Review 9.  Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?

Authors:  Solmaz Abdolrahimzadeh; Vittorio Scavella; Lorenzo Felli; Filippo Cruciani; Maria Teresa Contestabile; Santi Maria Recupero
Journal:  Biomed Res Int       Date:  2015-09-16       Impact factor: 3.411

Review 10.  Ocular manifestations of Sturge-Weber syndrome: pathogenesis, diagnosis, and management.

Authors:  Flavio Mantelli; Alice Bruscolini; Maurizio La Cava; Solmaz Abdolrahimzadeh; Alessandro Lambiase
Journal:  Clin Ophthalmol       Date:  2016-05-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.